7 Best Peptides for Menopause

What to Know Before Choosing a Peptide for Menopause

Menopause is driven by the loss of estrogen and progesterone, and no peptide currently reverses that shift. What peptide therapy can do is work on the downstream systems that estrogen influences: growth hormone output, skin collagen production, libido signaling, stress response, sleep regulation, and metabolic function. That makes the field genuinely useful for some symptoms and genuinely limited for others. Hot flashes in particular remain poorly addressed by any peptide to date.

A compound earned a slot on this list because people use it or are actively discussing it for menopause-related symptoms. That standard includes FDA-approved options, compounds available through telemedicine clinics, and research-only peptides whose use is tracked in community protocols. Evidence strength is described honestly for each entry rather than used as a filter for inclusion. If a compound's only backing is user-reported experience and animal data, that is what the entry says, and it still belongs on the list because the reader who is already researching it deserves a clear, honest account of where it stands.

These entries are numbered by how prominently each compound appears in research and documented real-world use for menopause-related goals. That is an ordering, not a recommendation of one compound over another. The right choice depends on which specific symptoms are the priority, individual health history, and guidance from a clinician familiar with this space.

One important context: the majority of women who find substantial relief from menopausal symptoms do so through hormone replacement therapy, and most practitioners treating this population use peptides as additions to that foundation rather than substitutes for it. That context shapes how each entry is written.

1. PT-141: For Menopause-Related Loss of Sexual Desire

PT-141, also known by its generic name bremelanotide, is the only peptide on this list with FDA approval for a condition directly related to menopause: hypoactive sexual desire disorder, or HSDD. Loss of sexual desire is among the most commonly reported and least openly discussed symptoms of menopause, and PT-141 addresses it through a mechanism that sets it apart from every other option in this category.

Where most treatments for sexual dysfunction work peripherally, increasing blood flow or lubrication, PT-141 acts centrally. It binds to melanocortin receptors in the brain, specifically the pathways involved in regulating sexual motivation, and works at the level of desire itself rather than physical response. That central mechanism is what made it worth putting through clinical trials, and those trials produced the approval it carries today.

The FDA approval covers HSDD in premenopausal women, and PT-141 is used off-label in postmenopausal women with the same complaint. Telemedicine clinics now prescribe it widely. Users who combine it with hormone replacement therapy commonly describe an additive benefit on desire, framing it as a useful tool alongside HRT rather than a replacement for it. It is self-administered by subcutaneous injection, typically used as needed before anticipated sexual activity rather than on a daily schedule.

The compound does not address hot flashes, sleep, body composition, or any of the other symptom clusters of menopause. Its role is specific, and its evidence is the strongest in this group precisely because it is narrow. For women whose primary complaint is low libido, it is the most clinically grounded option in the peptide space.

2. GHK-Cu: For Skin and Hair Changes

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, and it has become one of the most widely used peptides among women managing the skin and hair changes that menopause accelerates. Estrogen plays a significant role in maintaining skin thickness, collagen density, and hair follicle cycling, and its decline shows up visibly in many women as increased laxity, dryness, and hair shedding.

The mechanism behind GHK-Cu is reasonably well understood. It stimulates fibroblasts, the cells responsible for producing collagen and elastin, while also reducing the activity of matrix metalloproteinases, which are enzymes that break down existing collagen. It promotes the formation of new blood vessels in skin tissue, a process called angiogenesis, which supports both wound healing and general skin maintenance. The preclinical research for topical applications is substantial, and topical GHK-Cu is widely available in serums and creams without a prescription.

The important distinction is between topical and injectable forms. Topical GHK-Cu appears safe based on available data, has a long track record of use, and is considered appropriate for self-directed use. The injectable form is a different situation: its safety profile has not been established, long-term data is lacking, and practitioners generally do not recommend it outside of closely supervised protocols.

User-reported experience across menopause and skincare communities is broadly positive for the topical form, with consistent reports of reduced hair shedding, improved skin quality, and faster nail growth. Results in published research on skin biology support the topical application mechanism, though no controlled trial has specifically studied GHK-Cu in postmenopausal women.

3. Ipamorelin: For Sleep Quality and Body Composition

Ipamorelin is a growth hormone secretagogue, meaning it signals the pituitary gland to release more of the body's own growth hormone rather than introducing synthetic growth hormone from outside. That distinction matters: it produces a more physiologically patterned pulse of growth hormone, which translates to a cleaner side-effect profile compared to direct synthetic growth hormone use.

Menopause intersects with GH biology in a specific way. Growth hormone output declines with age in both men and women, and menopause accelerates several of the processes that GH normally helps regulate: sleep architecture, lean muscle maintenance, and body composition. Women in perimenopause and postmenopause frequently report worsening sleep quality and a shift toward more visceral fat with less lean tissue, even when diet and activity have not changed substantially.

Ipamorelin is frequently used for this cluster of complaints. The sleep benefit is one of the most consistently reported effects in the GH-secretagogue category, and improved sleep in turn affects energy, cognitive clarity, and mood. The body composition effect takes longer to manifest but is reported as meaningful by users who remain consistent.

No published clinical trial has examined Ipamorelin specifically in menopausal women. A 2006 study in the Journal of Clinical Endocrinology and Metabolism demonstrated sustained growth hormone and IGF-1 increases in healthy adults using CJC-1295, a related compound often combined with Ipamorelin, but the population studied was not postmenopausal women and the study was not designed to assess menopause symptoms. What exists for Ipamorelin in this population is off-label clinical use through telemedicine practices and user-reported experience from community protocols. The regulatory status has also been in flux: Ipamorelin was briefly placed on an FDA draft list of bulk substances that could not be compounded, then removed from that list in 2024 after the nominating party withdrew. Its compounding status remains under ongoing regulatory review.

4. CJC-1295: For Sarcopenia and Metabolic Slowdown

CJC-1295 is a growth hormone-releasing hormone analog, a synthetic version of the signal the hypothalamus uses to tell the pituitary to produce growth hormone. It has a longer half-life than the body's own GHRH, which means it sustains elevated growth hormone output over a longer window than a single natural pulse would. It is most often used in combination with Ipamorelin because the two work on complementary pathways.

The reason CJC-1295 appears specifically in menopause-adjacent conversations is its relevance to sarcopenia and visceral fat. Sarcopenia refers to the progressive loss of skeletal muscle mass and strength, a process that accelerates after menopause and is one of the most significant long-term health risks of the postmenopausal transition. Visceral fat, the metabolically active fat stored around abdominal organs, also increases after menopause as estrogen-mediated fat distribution patterns shift. Both of these processes are influenced by the GH and IGF-1 axis that CJC-1295 targets.

The clinical evidence picture is the same as for Ipamorelin: the 2006 JCEM study established that CJC-1295 produces sustained increases in growth hormone and IGF-1 in healthy adults, but it was not a menopause trial, and no dedicated randomized controlled trial of CJC-1295 for menopausal body composition changes has been published. Use in this population is off-label, driven by mechanistic reasoning and practitioner experience rather than direct clinical validation.

Practitioners who prescribe CJC-1295 in perimenopausal and postmenopausal women cite the combination of lean mass support and sleep quality improvement as the primary rationale. The FDA has noted cardiovascular effects, including increased heart rate, and immunogenicity as risks associated with this compound class.

5. Sermorelin: For Energy and Overall Vitality

Sermorelin is an older GHRH analog, shorter in structure than CJC-1295, and in some ways better characterized in clinical contexts because it was used therapeutically in adults before the more recent generation of secretagogues arrived. It stimulates the pituitary's own growth hormone production, and practitioners who prescribe it for perimenopausal and menopausal women typically frame it as support for the broader vitality picture: energy, lean mass maintenance, and the general sense of metabolic function that tends to erode in the years around menopause.

The distinction practitioners draw between Sermorelin and CJC-1295 is mostly one of duration and magnitude. Sermorelin produces a shorter-lived GH stimulus; CJC-1295 sustains it longer. For some women, the more moderate profile of Sermorelin feels more appropriate, particularly earlier in the perimenopause transition when the goal is restoring a natural-feeling rhythm rather than aggressively countering an established deficit.

Sermorelin is available through telemedicine clinics and is one of the more accessible peptides in this category from a prescribing standpoint. No menopause-specific human trial exists, and the evidence supporting its use in this population combines general GH-optimization data with off-label clinical experience. Users report improved energy and a gradual positive shift in body composition over several months of consistent use, with results described as subtle rather than dramatic, particularly without concurrent dietary and exercise changes.

The compound is not a direct answer to vasomotor symptoms, mood instability, or the sexual health complaints that bring many women to this conversation. Its place in the list reflects how consistently it appears in clinician-guided protocols for the energy and body composition aspects of the menopause transition.

6. BPC-157: For Joint Pain and Gut Dysfunction

BPC-157 is a synthetic peptide derived from a protein found in gastric juice, and it has developed one of the larger followings in the broader peptide community for its anti-inflammatory and tissue-repair properties. Among women managing menopause, it comes up most often in two contexts: joint pain, which frequently worsens in the perimenopausal transition, and gut dysfunction, including the shifts in gut motility and barrier function that some women notice in midlife.

The mechanism involves both anti-inflammatory signaling and the promotion of angiogenesis in damaged tissue, which accelerates delivery of the materials needed for repair. In animal studies, the compound has shown consistent effects on tendon healing, gut lining integrity, and inflammation reduction. The preclinical literature for BPC-157 is substantial. The human data is not.

No human clinical trial has been published examining BPC-157 for any menopausal symptom. What exists in the human context is largely user-reported: community forums contain consistent accounts of reduced joint aches, improved gut comfort, and what some users describe as overall tissue resilience. These reports appear across both injectable and oral forms of the compound.

The regulatory situation with BPC-157 is a significant practical consideration. The FDA has classified it as a Category 2 bulk drug substance, which means commercial pharmacies cannot legally compound it. That classification reflects the FDA's assessment that existing human safety data is insufficient. The compound is also banned by the World Anti-Doping Agency. Women with a history of cancer or active cancer should be aware that practitioners flag BPC-157's pro-angiogenic properties as a theoretical concern, though no human study has established a causal link to tumor progression. The evidence base is experiential and preclinical rather than clinical, and the regulatory constraints are real ones that belong in the picture.

7. Epitalon: For Sleep and Circadian Disruption

Epitalon is a synthetic tetrapeptide, a chain of four amino acids, developed from research on the pineal gland. It appears in menopause-related conversations because sleep deterioration is one of the most consistently reported and most quality-of-life-affecting symptoms of the transition, and Epitalon's proposed mechanism targets sleep and circadian regulation directly.

The compound is thought to work by influencing melatonin production in the pineal gland and restoring the gland's regulatory function, which tends to decline with age. Some research has examined Epitalon's effects on telomere length in human cells, and it is cited in longevity circles as having more human-cell data than many compounds in the longevity space, though the scale and rigor of that data is limited and the compound has not been studied in randomized controlled trials for any application.

In menopause specifically, no published human trials exist. Epitalon is not FDA-approved for any use in the United States and is available only through research-chemical channels domestically. Its use in the menopause context is community-reported and driven by mechanistic reasoning about pineal function and sleep architecture rather than clinical validation.

Users who report positive outcomes most often describe improved sleep onset, reduced nighttime waking, and a more regular sleep-wake pattern over several weeks of use. Community protocols typically describe it as a periodic course rather than a continuous daily compound. The evidence here is experiential, the mechanistic rationale is real if unproven in humans, and for women whose dominant complaint is sleep disruption the compound is worth knowing about even at that level of evidence.

How These Peptides Compare

Frequently Asked Questions

Is any peptide FDA-approved specifically for menopause?

One peptide on this list carries FDA approval for a menopause-related condition: PT-141 (bremelanotide) is approved for hypoactive sexual desire disorder, though its approval covers premenopausal women and its use in postmenopausal women is off-label. No peptide has been FDA-approved specifically for hot flashes, sleep disruption, sarcopenia, or any other core menopausal complaint. Veozah (fezolinetant), a non-hormonal FDA-approved treatment for hot flashes, is sometimes discussed alongside peptides in community forums but is not itself a peptide.

Can peptides replace hormone replacement therapy for menopause?

The short answer is no, and practitioners who use both consistently frame peptides as additions to HRT rather than replacements for it. HRT addresses the underlying hormonal deficit directly, and for the majority of menopausal symptoms, including hot flashes and night sweats, it remains the most effective option available. Peptides work on downstream systems that estrogen influences, things like growth hormone output, skin collagen, and libido signaling, and they tend to work better when those downstream systems are already supported by an adequate hormonal foundation.

Are these peptides safe to use during menopause?

The honest answer is that long-term safety data for most of these compounds in postmenopausal women is limited or absent. A 2024 systematic review in the American Journal of Sports Medicine concluded that human safety data remains unknown for most peptides used in the perimenopause context. PT-141 has the most established safety profile because it has been through clinical trials. Women with a personal or family history of hormone-sensitive cancers should discuss any peptide use with a physician before starting, as some compounds carry theoretical concerns related to pro-angiogenic activity.

Why do community reports on these peptides vary so much?

No single peptide showed consistent effectiveness across user communities in the research for this guide. Outcomes vary based on which specific symptom is being targeted, whether the person is also using HRT, individual differences in physiology and absorption, and the purity of the compound itself. Some users describe dramatic improvements; others report no noticeable change from the same compound on comparable protocols. That variability is genuinely present in the data and reflects the absence of controlled human trials that would otherwise establish predictable response rates.

How are these peptides typically obtained?

PT-141 is available by prescription through telemedicine platforms and traditional clinics. Sermorelin and the GH-secretagogue class including Ipamorelin and CJC-1295 are available through some telemedicine prescribers. GHK-Cu in topical form is widely available as an over-the-counter skincare ingredient. BPC-157 cannot be legally compounded by commercial pharmacies due to its FDA Category 2 classification, limiting its availability to research-chemical channels that do not carry the same purity and quality assurances as compounded pharmaceuticals. Epitalon is not approved in the US and exists only as a research chemical domestically. Regulatory status in this space changes, and current access should be verified with a clinician or an up-to-date regulatory source.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for menopause in one place.